Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy

American Heart Journal

Volumn 152, Issue 4, 2006, Pages 777-784

  Yood, Marianne Ulcickas ^a,b,c   McCarthy, Bruce D ^b,d   Kempf, Judy ^e   Kucera, Gena P ^b   Wells, Karen ^b   Oliveria, Susan ^a,f   Stang, Paul ^g,h  

^a EpiSource   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Allina Hospitals & Clinics   (United States)

^e ASTRAZENECA   (United Kingdom)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g Galt Associates Inc   (United States)

^h WEST CHESTER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; CAUCASIAN; COMPARATIVE STUDY; COMPUTER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEALTH CARE; HUMAN; HYPERLIPIDEMIA; INCOME; LABORATORY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; SEX; TIME SERIES ANALYSIS; UNITED STATES;

AFRICAN AMERICANS; AGED; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GOALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; MALE; MEDICAL RECORDS; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33748689542     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.02.036     Document Type: Article

References (35)

1. Statistical Fact Sheet-Populations: African Americans and Cardiovascular Diseases. American Heart Association, 2003. Available at: http://www.americanheart.org/downloadable/heart/1075704252739FS01AF04.pdf. Accessed June 15, 2004.
2. Poulter N. Global risk of cardiovascular disease. Heart 89 Suppl 2 (2003) 2-5
3. Lee A.J., Gehlbach S., Homer D.W., et al. Medicare treatment differences for blacks and whites. Med Care 35 (1997) 1173-1189
4. Nelson K., Norris K., and Mangione C.M. Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 162 (2003) 929-935
5. Ayanian J.Z., Landon B.E., Landrum M.B., et al. Use of cholesterol-lowering therapy and related beliefs among middle-aged adults after myocardial infarction. J Gen Intern Med 17 (2002) 95-102
6. Benner J.S., Glynn R.J., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
7. Chong P.H., Tzallas-Pontikes P.J., Seeger J.D., et al. The low-density lipoprotein cholesterol-lowering effect of pravastatin and factors associated with achieving targeted low-density lipoprotein levels in an African-American population. Pharmacotherapy 20 (2000) 1454-1463
8. Ray W.A. Evaluating medication effects outside of clinical trials: new user designs. Am J Epidemiol 158 (2003) 915-920
9. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269 (1993) 3015-3023
10. National Cholesterol Education Program (NCEP) Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001) 2486-2497
11. Bradley E.H., Herrin J., Wang Y., et al. Racial and ethnic differences in time to acute hospital reperfusion therapy for patients hospitalized with myocardial infarction. JAMA 292 (2004) 1563-1572
12. Schectman J.M., Bovbjerg V.E., and Voss J.D. Predictors of medication-refill adherence in an indigent rural population. Med Care 40 (2002) 1294-1300
13. Charles H., Good C.B., Hanusa B.H., et al. Racial differences in adherence to cardiac medications. J Natl Med Assoc 95 (2003) 17-22
14. Huxtable L.M., and Borowski D. Evaluation of lipid-lowering therapies at an ethnically diverse clinic. Am J Health Syst Pharm 60 (2003) 1282-1283
15. Lackland D.T., Lin Y., Tilley B.C., et al. An assessment of racial differences in clinical practices for hypertension at primary care sites for medically underserved patients. J Clin Hypertens (Greenwich) 6 (2004) 26-33
16. Heisler M., Smith D.M., Hayward R.A., et al. Racial disparities in diabetes care processes, outcomes, and treatment intensity. Med Care 41 (2003) 1221-1232
17. Ho P.M., Maynard C., Starks H., et al. Outcomes in patients with coronary heart disease who do not undergo lipid testing. Am J Cardiol 91 (2003) 986-988
18. Dressler D.D., and Jacobson T.A. Effects of race on lipid-lowering management in hospitalized patients with coronary heart disease. Am J Cardiol 93 (2004) 1167-1170
19. Williams M.L., Morris II M.T., Ahmad U., et al. Veterans Affairs of New Jersey Healthcare System (VANJHCS) research group. Racial differences in compliance with NCEP-II recommendations for secondary prevention at a Veterans Affairs medical center. Ethn Dis 12 Suppl 1 (2002) 58-62
20. Gans K.M., Burkholder G.J., Risica P.M., et al. Baseline fat-related dietary behaviors of white, Hispanic, and black participants in a cholesterol screening and education project in New England. J Am Diet Assoc 103 (2003) 699-706
21. Patterson R.E., Kristal A., Rodabough R., et al. Change in food sources of dietary fat in response to an intensive low-fat dietary intervention: early results from the Women's Health Initiative. J Am Diet Assoc 103 (2003) 454-460
22. Gates G., and McDonald M. Comparison of dietary risk factors for cardiovascular disease in African American and white women. J Am Diet Assoc 97 (1997) 1394-1400
23. Schoenborn C.A., Adams P.F., Barnes P.M., et al. Health behaviors of adults: United States, 1999-2001. National Center for Health Statistics. Vital Health Stat 10 (2004). http://www.cdc.gov/nchs/data/series/sr_10/sr10_219.pdf [Available at: http://www.cdc.gov/nchs/data/series/sr_10/sr10_219.pdf. Accessed June 9, 2004]
24. Crespo C.J., Smit E., Andersen R.E., et al. Race/ethnicity, social class and their relation to physical inactivity during leisure time: results from the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Prev Med 18 (2000) 46-53
25. Richter D.L., Wilcox S., Greaney M.L., et al. Environmental, policy, and cultural factors related to physical activity in African American women. Women Health 36 (2002) 91-109
26. van Sluijs E.M.F., van Poppel M.N.M., and van Mechelen W. Stage-based lifestyle interventions in primary care: are they effective?. Am J Prev Med 26 (2004) 330-343
27. Plescia M., and Groblewski M. A community-oriented primary care demonstration project: refining interventions for cardiovascular disease and diabetes. Ann Fam Med 2 (2004) 103-109
28. Chasman D.I., Posada D., Subrahmanyan L., et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291 (2004) 2821-2827
29. Jamersan K., and DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med 101 (1996) 22S-32S
30. Exner D.V., Dries D.L., Domanski M.J., et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared to white patients with left ventricular dysfunction. N Engl J Med 344 (2001) 1351-1357
31. Yancy C.W., Fowler M.B., Colucci W.S., et al. US Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 344 (2001) 1358-1365
32. Ferdinand K.C., Serrano C.C., and Ferdinand D.P. Contemporary treatment of heart failure: is there evidence to support a unique strategy for African-Americans? Con position. Curr Hypertens Rep 4 (2002) 311-318
33. Cohn J.N. Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Pro position. Curr Hypertens Rep 4 (2002) 307-310
34. Fenves A., and Ram V.S. Are angiotensin converting enzyme inhibitors and angiotensin receptor blockers becoming the treatment of choice in African-Americans?. Curr Hypertens Rep 4 (2002) 286-289
35. Ferdinand K.C. Coronary heart disease and lipid-modifying treatment in African American patients. Am Heart J 147 (2004) 774-782